within Pharmacolibrary.Drugs.ATC.L;

model L01BB04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.37,
    Cl             = 0.0004783333333333333,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.48,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006166666666666667,
    Tlag           = 25.2,            
    Vdp             = 0.476,
    k12             = 29.6,
    k21             = 29.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cladribine is a purine nucleoside analogue used primarily as an antineoplastic agent for the treatment of hematological malignancies such as hairy cell leukemia and multiple sclerosis. Cladribine is approved for use in relapsing forms of multiple sclerosis and has demonstrated efficacy as an immunomodulatory and cytotoxic agent due to its selective cytotoxicity for lymphocytes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with multiple sclerosis following oral administration</p><h4>References</h4><ol><li><p>Hermann, R, et al., &amp; Dong, JQ (2025). Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre-Menopausal Women With Relapsing Multiple Sclerosis. <i>Clinical and translational science</i> 18(4) e70204–None. DOI:<a href=&quot;https://doi.org/10.1111/cts.70204&quot;>10.1111/cts.70204</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40170281/&quot;>https://pubmed.ncbi.nlm.nih.gov/40170281</a></p></li><li><p>Liliemark, J (1997). The clinical pharmacokinetics of cladribine. <i>Clinical pharmacokinetics</i> 32(2) 120–131. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199732020-00003&quot;>10.2165/00003088-199732020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9068927/&quot;>https://pubmed.ncbi.nlm.nih.gov/9068927</a></p></li><li><p>Savic, RM, et al., &amp; Karlsson, MO (2017). Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. <i>Clinical pharmacokinetics</i> 56(10) 1245–1253. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0516-6&quot;>10.1007/s40262-017-0516-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28255849/&quot;>https://pubmed.ncbi.nlm.nih.gov/28255849</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BB04;
